| dc.contributor.author | Musoke, Philippa M. | |
| dc.contributor.author | Owor, Maxensia | |
| dc.contributor.author | Young, Alicia M. | |
| dc.contributor.author | Lubega, Irene R. | |
| dc.contributor.author | Brown, Elizabeth R. | |
| dc.contributor.author | Mmiro, Francis A. | |
| dc.contributor.author | Mofenson, Lynne M. | |
| dc.contributor.author | Jackson, J. Brooks | |
| dc.contributor.author | Fowler, Mary Glenn | |
| dc.contributor.author | Guay, Laura A. | |
| dc.date.accessioned | 2013-07-05T08:07:56Z | |
| dc.date.available | 2013-07-05T08:07:56Z | |
| dc.date.issued | 2008-10-01 | |
| dc.identifier.citation | Musoke. P.M., Owor, M., Young, A.M., Lubega, I.R., Brown, E.R., Mmiro, F.A., Mofenson, L.M., Jackson, J.B., Fowler, M.G., Guay, L.A. (2008). Total lymphocyte count: not a surrogate marker for risk of death in HIV infected Ugandan children. Journal of Acquired Immune Deficiency Syndromes, 49(2) | en_US |
| dc.identifier.issn | 1525-4135 | |
| dc.identifier.uri | http://hdl.handle.net/10570/1821 | |
| dc.description | National Institute of Health- Author Manuscript | en_US |
| dc.description.abstract | Objectives—To determine the utility of Total Lymphocyte Count (TLC) in predicting the 12 month mortality in HIV infected Ugandan children; to correlate TLC and CD4 cell %. Design—This is a retrospective data analysis of clinical and laboratory data collected prospectively on 128 HIV infected children in the HIVNET 012 trial. Methods—TLC and CD4 cell % measurements were obtained at birth, 14 weeks and 12, 24, 36, 48, and 60 months of age and assessed with respect to risk of death within 12 months. Results—Median TLC/ul (CD4 cell %) were 4150 (41%) at birth, 4900 (24%) at 12 months, 4300 (19%) at 24 months, 4150 (19 %) at 36 months, 4100 (18%) at 48 months and 3800 (20%) at 60 months. The highest risk of mortality within 12 months was 34–37% at birth and declined to 13– 15% at 24 months regardless of TLC measurement. The correlation between CD4 cell % and TLC was extremely low overall (r = 0.01). Conclusion—The TLC did not predict a risk of progression to death within 12 months and therefore TLC alone may not be a useful surrogate marker for determining those children in greatest need for antiretroviral therapy in HIV infected Ugandan children. | en_US |
| dc.description.sponsorship | This work was supported by (1) the HIV Network for Prevention Trials (HIVNET) and sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Dept. of Health and Human Services (DHHS), through contract N01-AI-35173 with Family Health International, contract N01-AI-45200 with Fred Hutchinson Cancer Research Center, and subcontract (N01-AI-35173-417) with Johns Hopkins University. (2) the HIV Prevention Trials Network (HPTN) sponsored by the NIAID, National Institutes of Child Health and Human Development (NICH/HD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (U01-AI-46745, U01-AI-48054, and U01-AI-068613), and the International Maternal Pediatric Adolescent AIDS Clinical Trials Group sponsored by the NIAID and NICH/HD (U01-AI-068632, U01-AI-069530). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIAID. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott, Williams & Wilkins | en_US |
| dc.subject | Total Lymphocyte Count | en_US |
| dc.subject | HIV/AIDS | en_US |
| dc.subject | Africa | en_US |
| dc.subject | Children | en_US |
| dc.subject | Mortality | en_US |
| dc.subject | CD4 cell count | en_US |
| dc.title | Total lymphocyte count: not a surrogate marker for risk of death in HIV infected Ugandan children | en_US |
| dc.type | Journal article, peer reviewed | en_US |
